Keros Therapeutics (KROS) News Today $53.89 -0.25 (-0.46%) (As of 10:31 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Keros Therapeutics Third Quarter 2024 Earnings: US$1.41 loss per share (vs US$1.33 loss in 3Q 2023)November 15, 2024 | sg.finance.yahoo.comWedbush Predicts Weaker Earnings for Keros TherapeuticsNovember 13, 2024 | americanbankingnews.comHC Wainwright Issues Pessimistic Forecast for KROS EarningsNovember 13, 2024 | americanbankingnews.comWhat is Leerink Partnrs' Forecast for KROS FY2024 Earnings?November 12, 2024 | americanbankingnews.comWilliam Blair Has Bearish Forecast for KROS FY2024 EarningsNovember 11, 2024 | americanbankingnews.comFY2024 Earnings Estimate for KROS Issued By HC WainwrightKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Stock analysts at HC Wainwright cut their FY2024 earnings estimates for Keros Therapeutics in a research note issued to investors on Thursday, November 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($November 11, 2024 | marketbeat.comWhat is Leerink Partnrs' Estimate for KROS FY2024 Earnings?Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Analysts at Leerink Partnrs dropped their FY2024 EPS estimates for Keros Therapeutics in a research report issued on Thursday, November 7th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of ($5.26) per shareNovember 11, 2024 | marketbeat.comWedbush Equities Analysts Cut Earnings Estimates for KROSKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Stock analysts at Wedbush decreased their FY2024 earnings estimates for shares of Keros Therapeutics in a research report issued to clients and investors on Thursday, November 7th. Wedbush analyst Y. Zhong now forecasts that the company willNovember 11, 2024 | marketbeat.comEquities Analysts Offer Predictions for KROS FY2024 EarningsKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Research analysts at William Blair lowered their FY2024 EPS estimates for shares of Keros Therapeutics in a report released on Wednesday, November 6th. William Blair analyst M. Phipps now forecasts that the company will post earnings per sharNovember 11, 2024 | marketbeat.comPromising Growth Potential for Keros Therapeutics Driven by Robust Clinical Pipeline and Upcoming Data ReleasesNovember 8, 2024 | markets.businessinsider.comPromising Developments and Financial Stability Justify Buy Rating for Keros TherapeuticsNovember 8, 2024 | markets.businessinsider.comKeros Therapeutics: Strong Buy Rating Backed by Strategic Pipeline Progress and Favorable Trial OutcomesNovember 8, 2024 | markets.businessinsider.comPromising Pipeline: Keros Therapeutics’ Cibotercept and KER-065 Drive Buy Rating with $100 Price TargetNovember 7, 2024 | markets.businessinsider.comPositive Outlook and Buy Rating for Keros Therapeutics Amid Promising Developments and Strong Financial PositionNovember 7, 2024 | markets.businessinsider.comKeros Therapeutics (NASDAQ:KROS) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $100.00 price target on shares of Keros Therapeutics in a research note on Thursday.November 7, 2024 | marketbeat.comQ3 Earnings Forecast for KROS Issued By WedbushKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities researchers at Wedbush issued their Q3 2024 earnings per share estimates for shares of Keros Therapeutics in a research note issued to investors on Monday, November 4th. Wedbush analyst Y. Zhong expects that the company will post earNovember 7, 2024 | marketbeat.comKeros Therapeutics to Present at Guggenheim ConferenceNovember 7, 2024 | markets.businessinsider.comKeros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial ResultsNovember 6, 2024 | globenewswire.comKeros Therapeutics initiated with a Buy at JefferiesNovember 6, 2024 | markets.businessinsider.comJefferies starts Keros with Buy, sees potential $2B in peak salesNovember 6, 2024 | markets.businessinsider.comTruist Financial Sticks to Their Buy Rating for Keros Therapeutics (KROS)November 6, 2024 | markets.businessinsider.comKeros Therapeutics to Present at the Guggenheim Healthcare Innovation ConferenceNovember 6, 2024 | globenewswire.comAnalysts Set Expectations for KROS Q4 EarningsKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Research analysts at Wedbush issued their Q4 2025 earnings per share estimates for Keros Therapeutics in a report released on Monday, November 4th. Wedbush analyst Y. Zhong anticipates that the company will earn ($1.27) per share for the quarNovember 6, 2024 | marketbeat.comWedbush Upgrades Keros Therapeutics (NASDAQ:KROS) to "Strong-Buy"Wedbush raised Keros Therapeutics to a "strong-buy" rating in a research note on Monday.November 6, 2024 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Now Covered by Jefferies Financial GroupJefferies Financial Group assumed coverage on shares of Keros Therapeutics in a report on Tuesday. They set a "buy" rating on the stock.November 5, 2024 | marketbeat.comKeros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and ExpositionNovember 5, 2024 | finance.yahoo.comEmerald Advisers LLC Takes Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Emerald Advisers LLC acquired a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 155,545 shares of the company's stock, valued at approximatelyNovember 3, 2024 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Down 9.9% in OctoberKeros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) was the recipient of a significant decline in short interest in the month of October. As of October 15th, there was short interest totalling 2,720,000 shares, a decline of 9.9% from the September 30th total of 3,020,000 shares. Based on an average daily volume of 337,800 shares, the days-to-cover ratio is currently 8.1 days.October 30, 2024 | marketbeat.comAssenagon Asset Management S.A. Raises Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)Assenagon Asset Management S.A. boosted its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 814.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 223,704 shares of the company's stock afterOctober 28, 2024 | marketbeat.comCantor Fitzgerald Weighs in on KROS FY2024 EarningsKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2024 earnings per share estimates for shares of Keros Therapeutics in a report issued on Thursday, October 24th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will postOctober 28, 2024 | marketbeat.comKeros Therapeutics initiated with an Overweight at Cantor FitzgeraldOctober 25, 2024 | markets.businessinsider.comKeros Therapeutics (NASDAQ:KROS) Earns Overweight Rating from Analysts at Cantor FitzgeraldCantor Fitzgerald initiated coverage on Keros Therapeutics in a research report on Thursday. They set an "overweight" rating for the company.October 24, 2024 | marketbeat.comScotiabank Initiates Coverage of Keros Therapeutics (KROS) with Sector Outperform RecommendationOctober 16, 2024 | msn.comKeros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical OfficerOctober 16, 2024 | finance.yahoo.comKeros Therapeutics (NASDAQ:KROS) Now Covered by ScotiabankScotiabank started coverage on shares of Keros Therapeutics in a research report on Wednesday. They set a "sector outperform" rating on the stock.October 16, 2024 | marketbeat.comShort Interest in Keros Therapeutics, Inc. (NASDAQ:KROS) Declines By 13.7%Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) saw a significant drop in short interest in September. As of September 30th, there was short interest totalling 3,020,000 shares, a drop of 13.7% from the September 15th total of 3,500,000 shares. Based on an average daily trading volume, of 346,000 shares, the days-to-cover ratio is presently 8.7 days.October 16, 2024 | marketbeat.comRenaissance Technologies LLC Invests $654,000 in Keros Therapeutics, Inc. (NASDAQ:KROS)Renaissance Technologies LLC bought a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 14,300 shares of the company's stock, valued at approximatelyOctober 9, 2024 | marketbeat.comMarshall Wace LLP Has $1.02 Million Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)Marshall Wace LLP trimmed its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 91.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,377 shares of the company's stock after sellinOctober 8, 2024 | marketbeat.com19,832 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by Squarepoint Ops LLCSquarepoint Ops LLC acquired a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 19,832 shares of the company'October 7, 2024 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comTruist Financial Reaffirms Their Buy Rating on Keros Therapeutics (KROS)October 3, 2024 | markets.businessinsider.comNantahala Capital Management LLC Grows Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Nantahala Capital Management LLC raised its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 28.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 378,807 shares of the company'sOctober 1, 2024 | marketbeat.comPoint72 Asset Management L.P. Cuts Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Point72 Asset Management L.P. reduced its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 61.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 370,350 shares of the cSeptember 30, 2024 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Blue Owl Capital Holdings LPBlue Owl Capital Holdings LP trimmed its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 8.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 157,633 shares of the company's stock after sellingSeptember 28, 2024 | marketbeat.comFred Alger Management LLC Has $2.24 Million Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Fred Alger Management LLC lessened its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 25.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 48,993 shares of the company'sSeptember 27, 2024 | marketbeat.comDarwin Global Management Ltd. Boosts Stake in Keros Therapeutics, Inc. (NASDAQ:KROS)Darwin Global Management Ltd. boosted its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 6.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,525,902 shares of the company's sSeptember 26, 2024 | marketbeat.com3 Best Stocks to Buy Now, 9/23/2024, According to Top AnalystsSeptember 24, 2024 | msn.comKeros Therapeutics: A Promising Bet on TGF-β Pathway Innovations and Management’s Drug Development AcumenSeptember 23, 2024 | markets.businessinsider.comIntegral Health Asset Management LLC Acquires 45,000 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)Integral Health Asset Management LLC lifted its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 112.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 85,000 shares of the compaSeptember 23, 2024 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Receives New Coverage from Analysts at GuggenheimGuggenheim began coverage on Keros Therapeutics in a report on Monday. They set a "buy" rating and a $96.00 price target on the stock.September 23, 2024 | marketbeat.com Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address My #1 Pre IPO Trade for 2025 – NAME and TICKER (Ad)One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report... The Next SpaceX Pre-IPO KROS Media Mentions By Week KROS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KROS News Sentiment▼-0.920.46▲Average Medical News Sentiment KROS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KROS Articles This Week▼13▲KROS Articles Average Week Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Scholar Rock News Y-mAbs Therapeutics News Amarin News FibroGen News Madrigal Pharmaceuticals News Roivant Sciences News Ascendis Pharma A/S News Legend Biotech News Elanco Animal Health News Lantheus News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KROS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
